profit from every ₹100 of sales.
₹0₹100
CARE Ratings
₹1,595.10-0.19% today
+3.4% in 1 year
1-year low ₹1,412.501-year high ₹1,800.40
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹28.09 for every ₹1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What CARE Ratings sold, what it kept, and what it did with the cash.
Sales went from ₹2.79 billion in 2023 to ₹4.73 billion in 2026, with ₹1.71 billion of profit last year.
SalesProfit
CARE Ratings handed back 42% of the cash it generated last year.
₹584M
Free cash flow 2026₹1.4B
Bought back its own shares–
Paid as dividends₹584M
Cash vs. debt₹426M vs. ₹262M
CARE Ratings vs. similar companies
CARE Ratings grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| CARE Ratings | 28.1× · Fair price | ||
 S&P Global | 30.7× · Expensive | ||
 CME Group | 27.9× · Fair price | ||
 Intercontinental Exchange | 30.1× · Expensive | ||
 Moody's | 35.6× · Expensive |
AI analysis
An AI analyst reads CARE Ratings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 2,790 | 3,317 | 4,023 | 4,731 | |
| 1,549 | 1,817 | 2,286 | 2,752 | |
| 946 | 1,027 | 1,444 | 1,836 | |
| 1,373 | 1,588 | 2,061 | 2,522 | |
| 835 | 1,005 | 1,372 | 1,712 | |
| 28.17 | 33.67 | 45.69 | – | |
| 55.5% | 54.8% | 56.8% | 58.2% | |
| 33.9% | 31.0% | 35.9% | 38.8% | |
| 29.9% | 30.3% | 34.1% | 36.2% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 7,696 | 8,418 | 9,577 | 11,047 |
| Cash | 494 | 383 | 488 | 426 |
| Total debt | 175 | 196 | 238 | 262 |
| Total liabilities | 906 | 1,172 | 1,422 | 1,616 |
| 6,722 | 7,171 | 8,063 | 9,324 | |
| 30 | 30 | 30 | – | |
| 13.8% | 15.1% | 17.6% | 18.6% | |
| 12.4% | 14.0% | 17.0% | 18.4% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 822 | 909 | 1,230 | 1,476 | |
| 115 | 92 | 147 | 83 | |
| 707 | 817 | 1,082 | 1,393 | |
| Dividends paid | 598 | 669 | 549 | 584 |
| 19 | 0 | – | – | |
| 5 | 27 | 19 | 18 |
Valuation
- 28.1×
- –
- –
- 5.2×
- 10.2×
- 34.5×
- 19.0×
- 2.9%
- 3.6%
- 1.2%
Profitability
- 58.2%
- 38.8%
- 36.2%
- –
- 18.6%
- 16.3%
- –
- –
- –
- –
Growth
- +19.2%
- –
- –
- –
- +0.4%
Financial health
- -0.1×
- 0.03
- –
- 95.7×
- 5.76
- –
- –
How it ranks in Financial Services
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 9%of 854
Top 20%of 733
Bottom 17%of 876
Top 25%of 878
Bottom 33%of 929
1.2%of the share price, paid each year
On $1,000 invested$12a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
34.1% of its profit
Room to growStretchedMore than it earns: 41.9%
News
My wife has dementia and may outlive me. How do we prepare for long-term memory care?MarketWatch · Nov 14, 2026The lonely labor of caregiving: ‘You shouldn’t have to be rich to take care of the people you love’MarketWatch · Nov 14, 2026Electromed targets $1.05M–$1.15M home care revenue per rep as CEO plans April 2027 retirementSeeking Alpha · Nov 11, 2026Medicare used AI to pre-approve patient care, and it immediately led to a large drop in medical servicesMarketWatch · Oct 31, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
5/7Passes 5 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
72Pass
Benjamin Graham
58No pass
Philip Fisher
75Pass
Peter Lynch
92Pass
Joel Greenblatt
35No pass
Charlie Munger
72Pass
Terry Smith
67Pass
Questions about CARE Ratings
Is CARE Ratings a good stock to buy?
A strong, very profitable business at a fair price. 5 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the CARE Ratings AI analysis
What does CARE Ratings do?
CARE Ratings Limited, a credit rating agency, provides various rating and related services in India and internationally. It is in Financial Data & Stock Exchanges, based in Mumbai, India.
Does CARE Ratings pay a dividend?
Yes. At today's price the dividend is 1.2% a year, about 34% of its yearly profit. In 2026 it paid out ₹584 million in dividends.
Is CARE Ratings stock halal?
Yes. CARE Ratings passes our halal screen: its business is permitted and its debt is 0.5% of its market value, under the 30% limit. How we check
How has CARE Ratings stock done over the past year?
Up 3.4% over the past twelve months, to ₹1,595.10. It traded between ₹1,412.50 and ₹1,800.40 and is 11.4% below its high.
Who are CARE Ratings's competitors?
The largest listed companies in the same industry are S&P Global, CME Group, Intercontinental Exchange and Moody's. The peers table on this page compares their profit, growth and price with CARE Ratings's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.